ClinicalTrials.gg
RecruitingNCT07064135IMACSUpdated Nov 13, 2026

Improved Medication and Care to Achieve Lipid Targets After Carotid Surgery

An interventional study of Prompt Medication Adjustment and Intensive Follow-up and Standard Care in Dyslipidaemias and Carotid Artery Stenoses, sponsored by Barmherzige Brüder Linz. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Barmherzige Brüder Linz · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 13, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to find out if patients who receive extra support stay on their cholesterol-lowering therapy and therefore have lower cholesterol levels after 4 months. Extra support means regular phone calls and close monitoring before and after carotid artery surgery. The study compares this approach to usual care.

Participants will:

Be randomly assigned to either standard care or extra support for 4 months. Receive cholesterol-lowering treatment and attend follow-up visits.

Read the detailed description

Cardiovascular risk factors are one of the leading causes of morbidity and mortality worldwide. Improving these often fails due to the lack of low-threshold access to specialized medical care. Especially in vascular surgery departments with multimorbid patients, optimizing the management of risk factors-particularly cholesterol-is essential.

This exploratory randomized controlled pilot study aims to investigate the effects of pharmacological optimization of cholesterol management after carotid surgery with subsequent follow-up visits. For this purpose, 50 patients who are undergoing carotid surgery due to carotid stenosis will be randomized into two groups. In Group 1, 25 patients who have not reached the lipid target at the time of surgery will be included and re-evaluated regarding their therapy after 2 months and undergo another ambulatory cholesterol check after 4 months. In Group 2, 25 patients who also have not reached the lipid target at the time of surgery will be included and, after optimization of therapy during the hospital stay, will undergo an ambulatory cholesterol check after 4 months.

02

Conditions studied

  • Dyslipidaemias
  • Carotid Artery Stenoses

Browse trials for

Keywords

  • LDL-C lowering
  • Carotid Endarterectomy
  • Statins
  • Lipid Management
  • Secondary Prevention
03

In context

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

This study's planned enrollment of 50 is below the median of 102 across 192 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

Barmherzige Brüder Linz is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >17 years
  • Diagnosed carotid artery stenosis
  • Planned carotid endarterectomy
  • LDL cholesterol >55 mg/dL
  • Willingness to participate, documented by written

Exclusion criteria

Exclusion Criteria:

  • Ongoing treatment with PCSK9 inhibitors
  • Carotid surgery for reasons other than stenosis (e.g., traumatic injury)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intensive Follow-up

    Participants in this arm receive prompt adjustment of lipid-lowering medication to achieve target LDL-C levels, combined with intensive follow-up visits and laboratory monitoring 6-8 weeks post-surgery to optimize lipid management.

    Behavioral: Prompt Medication Adjustment and Intensive Follow-up

  • Active comparator
    Standard Care

    Participants in this arm receive standard postoperative care according to current guidelines, including routine follow-up and lipid management without additional early intervention or intensive monitoring.

    Other: Standard Care

Interventions

  • BehavioralPrompt Medication Adjustment and Intensive Follow-up

    Participants receive prompt adjustment of lipid-lowering therapy perioperatively and 6-8 weeks after carotid endarterectomy to achieve guideline-recommended LDL-C targets, combined with intensive follow-up visits and laboratory monitoring. Intensive follow-up visits and laboratory monitoring of lipid parameters are performed at 6-8 weeks and again at 12-16 weeks postoperatively to optimize lipid management.

  • OtherStandard Care

    Participants receive standard postoperative care according to guidelines, including lipid management and routine follow-up without additional early intervention or intensive monitoring. Lipid parameters are assessed only once at 12-16 weeks postoperatively.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving the LDL-C target of <55 mg/dL

    Time frame: 12-16 weeks

07

Study locations

1 of 1 sites recruiting
  • Konventhospital Barmherzige Brüder
    Linz, Upper Austria 4020, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The plan for sharing individual participant data (IPD) has not yet been determined. Sharing may be considered in the future depending on ethical approval, participant consent, and data protection regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 51 non-industry interventional studies with no phase under Carotid Stenosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 23 months is below that.

Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 19 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2026 → Jul 2027 and completion Dec 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 14, 2025
StartActual
Aug 4, 2025
Primary completionEst.
Jul 2027was Jun 2026
CompletionEst.
Oct 2027was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
Konventhospital Barmherzige Brüder is now Recruiting
Nov 13, 2026
Primary completion
Jun 2026→Jul 2027
Nov 13, 2026
Study completion
Dec 2026→Oct 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    Konventhospital Barmherzige Brüder is now Recruiting
    Primary completion Jun 2026→Jul 2027
    Study completion Dec 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07064135
Lead sponsor
Barmherzige Brüder Linz
Collaborators
Johannes Kepler University of Linz
Responsible party
Rainer Hintenberger (Senior Physician, Department of Vascular Surgery, Barmherzige Brüder Linz) — Principal investigator
First posted
Jul 14, 2025
Start date
Aug 4, 2025
Primary completion
Jul 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Rainer Hintenberger, MD
Contact
rainer.hintenberger@bblinz.at
+43 676 4295509
Matthias Heinzl, MD
Contact
matthias.heinzl@bblinz.at
+43 676 5206829
Martin Clodi, Professor, MD
study director · Konventspital Barmherzige Brüder Linz
Juergen Falkensammer, Associate Professor, MD
study chair · Konventspital Barmherzige Brüder Linz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion